Shionogi & Co. Ltd.
http://www.shionogi.co.jp/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shionogi & Co. Ltd.
FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why
Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why
Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
Shionogi Still Hopeful For Xocova In US Despite Phase III Fail
Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Shionogi Healthcare Co., Ltd
- Shionogi Pharma Co., Ltd
- Shionogi Techno Advance Research Co., Ltd.
- Shionogi Administration Service Co., Ltd.
- Shionogi Business Partner Co., Ltd
- Shionogi Marketing Solutions Co., Ltd
- Shionogi Career Development Center Co., Ltd.
- Shionogi Digital Science Co., Ltd.
- Shionogi Pharmacovigilance Center Co., Ltd.
- Aburahi AgroResearch Co., Ltd.
- Shionogi Smile Heart Co., Ltd
- UMN Pharma Inc.
- Shionogi B.V.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice